Mark Mullen, MD

Dr Mullen is a fourth-year psychiatry resident at Creighton University.

Articles

Exploring the Antisuicidal Effects of Lithium

Jesse Woo, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

November 14th 2024

A systematic review and meta-analysis showed moderate-quality evidence supporting lithium’s ability to lower mortality rates.

TMS for the Treatment of OCD

Tommy Sung, MD;Coralie Eilers, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

October 25th 2024

A new study shows that rTMS has moderate therapeutic effects on OCD severity.

The Safety of Psychostimulants or Atomoxetine for Patients With Psychotic Disorders

Nicholas Distefano, MD;Bransen Guild, DO;David Wilton, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

August 14th 2024

Evidence indicates that children and adolescents with ADHD have a more than 4-fold increased risk of schizophrenia spectrum and other psychotic disorders in adulthood compared with the general population.

Zuranolone for the Treatment of Adults With Major Depressive Disorder

Joshua Robak, MD;Lior Hilsenrath, MD;Abigail Jaeger, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

July 12th 2024

This randomized, placebo-controlled, phase 3 clinical trial showed that a 14-day treatment course of oral zuranolone 50 mg/day in MDD led to significantly greater improvements in depressive symptoms when compared with placebo.

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Longitudinal Study Looks at Risk of Cardiovascular Disease With Long-Term ADHD Medication Use

Masha Impallaria, MD;Haley Schuster, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

May 25th 2024

A study assessed the associations between the use of ADHD medications and CVD over the course of 14 years. Here's what the investigators found.

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Treatment-Resistant Geriatric Depression: Augmenting or Switching an Antidepressant

Lalangi Marasinghe, MD;Anvesh Jalasutram, MD;Phil Ryan, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

April 17th 2024

Recent research investigated the benefits and risks of augmentation compared with switching strategies for TRD in older adults.

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

Phase 3 Trials Examine Gantenerumab for Early Alzheimer Disease

Meagan Kubista, MD;Grethel Perez Meek, DO;Kyle Sramek, MD;Mark Mullen, MD;Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP

February 20th 2024

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.